{
    "clinical_study": {
        "@rank": "136061", 
        "arm_group": {
            "arm_group_label": "Famitinib Malate", 
            "arm_group_type": "Experimental", 
            "description": "Famitinib either at 4,8,13,20,27,36 mg, p.o. once daily"
        }, 
        "brief_summary": {
            "textblock": "Famitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and\n      antiangiogenic activities. This study is designed to evaluate the safety and tolerability of\n      Famitinib in patients with solid tumor"
        }, 
        "brief_title": "A Phase I Study of Famitinib Malate in Patients With Solid Tumor", 
        "condition": "Advanced Solid Tumor", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "1. To evaluate the safety and tolerability of Famitinib, and the maximum tolerated dose\n           (MTD) and dose-limiting toxicity (DLT).\n\n        2. To determine the pharmacokinetic profile of Famitinib and its metabolites .\n\n        3. To assess preliminary antitumor activity .\n\n        4. To determine preliminary dose and regimen for phase II study ."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological confirmed advanced or metastatic solid tumor\uff0cat least one measurable\n             lesion, larger than 10 mm in diameter by spiral CT scan(scanning layer \u2264 5 mm )\n\n          -  no standard therapy protocol available according to patients'condition\n\n          -  both sex, age 18 to 65\n\n          -  ECOG 0-1\n\n          -  Life expectancy more than 3 months\n\n          -  ALT,AST,TB\u22641.5(UNL),normal serum creatinine level, normal electrolyte or can be\n             corrected by medication\n\n          -  Subjects receiving damage caused by other therapeutic has been restored, the interval\n             more than six weeks since the last receiving nitroso or mitomycin; more than 4 weeks\n             since last receiving radiotherapy, other cytotoxic drugs or surgery\n\n          -  Understand and agree to sign informed consent form.\n\n        Exclusion Criteria:\n\n          -  Peripheral neuropathy \u2265 Grade 2(according to NCI-CTC 3.0)\n\n          -  Preexisting uncontrolled hypertension defined as more than 140/90 mmHg by using\n             single agent therapy, \uff1eGrade 1 (NCI-CTCAE 3.0 ) myocardial ischemia,\n             arrhythmia,cardiac function insufficiency\n\n          -  PT, APTT, TT, Fbg abnormal(PT>16s,APTT>43s,TT>21s,Fbg<2g/L), or have hemorrhagic\n             tendency or receiving the therapy of thrombolysis or anticoagulation\n\n          -  Active peptic ulcer\n\n          -  Previously medication include sunitinib\n\n          -  More than 4 weeks since the last clinical trial\n\n          -  Pregnant or lactating women\n\n          -  Women of childbearing age do not take effective contraceptive measures\n\n          -  Allergies, or known allergy history to components of the drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "29", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01762280", 
            "org_study_id": "FMTN-I"
        }, 
        "intervention": {
            "arm_group_label": "Famitinib Malate", 
            "intervention_name": "Famitinib  Malate Capsule", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Famitinib", 
            "Advanced Solid tumor", 
            "Phase I"
        ], 
        "lastchanged_date": "January 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "Cancer Institute and Hospital Chinese Academy of Medical Sciences"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of Famitinib Malate in Patients With Solid Tumor", 
        "overall_official": [
            {
                "affiliation": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences", 
                "last_name": "Jinwan Wang, M.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chinese Academy of Science Shanghai Institution of Materia Medica", 
                "last_name": "Dafang Zhong, Ph.D", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum tolerated dose(MTD)", 
                "safety_issue": "Yes", 
                "time_frame": "2 months"
            }, 
            {
                "measure": "Dose-limiting toxicity(DLT)", 
                "safety_issue": "Yes", 
                "time_frame": "2 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01762280"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Famitinib pharmacokinetic parameters , include AUC, Cmax, Tmax, and t1/2", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "measure": "Number of volunteers with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "2 months"
            }, 
            {
                "description": "The response of Famitinib on tumor.", 
                "measure": "Pharmacodynamics", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }
        ], 
        "source": "Jiangsu HengRui Medicine Co., Ltd.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Chinese Academy of Medical Sciences", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Chinese Academy of Sciences", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Jiangsu HengRui Medicine Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2009", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}